An oil-rich palm-berry extract taken mainly by men to ease the urinary symptoms of an enlarging prostate and to slow pattern hair loss. It gently lowers a strong form of testosterone and calms inflammation, and is well tolerated. Benefit is uncertain and quality-dependent: rigorous trials show no advantage over a dummy pill, while standardized extracts report real relief. (Full Review)

Protocol

Standard dose

320 mg / day

Standardized lipidosterolic extract, 85–95% fatty acids and sterols

Single versus split dosing

Once daily

160 mg twice daily is equally effective; once daily aids adherence

Half-life and timing

Take with largest meal

Evening meal supports absorption; keep timing consistent

Time to effect

Initial response

4–6 weeks

Minimum before urinary symptom response is assessed

Fair benefit

3–6 months

Continuous use for a fair judgment of benefit

Hair loss

Even longer

Effects, if any, take longer than urinary changes

Benefits

Medium: Relief of lower urinary tract symptoms of benign prostatic hyperplasia; favorable sexual-function and tolerability profile

Low: Pattern hair loss; chronic prostatitis and chronic pelvic pain; reduced prostate inflammation and volume

Speculative: Prostate cancer risk modulation; anti-androgen longevity and metabolic effects

Contraindications

Pregnancy, breastfeeding, or childbearing potential

Bleeding disorders or surgery within 2 weeks

Prior saw palmetto–associated liver injury or pancreatitis

Undisclosed use during PSA-based prostate screening

Key Interactions

Anticoagulants and antiplatelet drugs (warfarin, aspirin, clopidogrel)

Hormonal and anti-androgen therapies (finasteride, dutasteride, oral contraceptives, hormone therapy)

Iron supplements (reduced absorption)

Additive anti-androgen or bleeding supplements (pygeum, stinging nettle, fish oil, vitamin E, ginkgo, garlic)

Risk & Side Effects

Medium: Mild gastrointestinal effects; decreased libido and mild ejaculatory changes

Low: PSA reduction and screening interference; liver injury

Speculative: Increased bleeding risk; acute pancreatitis

Monitoring

Marker	Target	Why
International Prostate Symptom Score (IPSS)	0–7 (mild)	Tracks urinary symptom severity and response
Prostate-Specific Antigen (PSA)	< 1.0–1.5 ng/mL (younger men); < 2.5 ng/mL general	Screens for prostate abnormality and provides a baseline
Peak Urinary Flow Rate (Qmax)	> 15 mL/s	Objective measure of urinary obstruction
Post-Void Residual (PVR)	< 50 mL	Detects incomplete bladder emptying
Total and Free Testosterone	Mid-to-upper age-adjusted range	Context for anti-androgen effects and libido changes
Liver Enzymes (ALT, AST)	Within standard reference range	Screens for the rare liver injury

Cadence: Baseline, then reassess at ~3 months and every 6–12 months; earlier if new symptoms appear

Qualitative Assessment

Fewer nighttime awakenings to urinate and less daytime urgency
Stronger, more complete urinary stream and less straining
Improved sleep quality secondary to reduced nighttime urination
For hair-loss use, reduced shedding and subjective thickening on standardized photos
Absence of new digestive, sexual, or bleeding symptoms

Saw Palmetto for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment